Phase III clinical trial results of anamorelin in CACS
AstraZeneca confirmed on June 1, 2026 that its oral GLP-1 drug elecoglipron (AZD5004) hit the primary endpoints in two Phase 2b trials VISTA in obesity and SOLSTICE in type 2 diabetes and will present the full data at the American Diabetes Association 2026 Scientific Sessions on June 8
Handling Time: We handle shipments on business days (Monday - Friday), with a preparation time of 1-2 days
Improvement with progesterone withdrawal or suppression: Resolution or marked improvement of symptoms after: Stopping progesterone containing medications Suppressing ovulation (and therefore progesterone production) This response strongly supports progesterone hypersensitivity
Orlistat (Xenical, Alli) remains the most accessible pharmacological option, available both on NHS prescription and over-the-counter at lower strengths
Placental transfer of NAC (a class B medication) in humans has been documented with concentrations in the umbilical cord blood similar to maternal levels (Horowitz et al.)